Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VAG versus VA in elderly acute myeloid leukemia
ChiCTR2300078290Phase 3Recruiting
- Sponsor
- Beijing Chaoyang Hospital, Capital Medical University
- Start
- Dec 2023
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of venetoclax, azacitidine and filgrastim in acute myeloid leukemia (AML) (2 arms), sponsored by Beijing Chaoyang Hospital, Capital Medical University. Primary endpoint: Overall survival. Started Dec 2023; status: recruiting.
02
Drugs
venetoclaxazacitidinefilgrastim
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on ChiCTR2300078290.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300078290.